<DOC>
	<DOCNO>NCT01821625</DOCNO>
	<brief_summary>This study provide chronic hepatitis C ( CHC ) patient low platelet ( less 75x10^9/L ) opportunity undergo treatment possible cure virus . The main hepatitis C drug administer standard care , addition study drug eltrombopag . The investigator hypothesize provide eltrombopag CHC patient low platelet ( less 75x10^9/L ) permit initiation completion antiviral triple therapy boceprevir , ribavirin , pegylated-interferon .</brief_summary>
	<brief_title>Study Quadruple Therapy With Eltrombopag Chronic Hepatitis C</brief_title>
	<detailed_description>SQUELCH-C investigator-initiated , single arm , non-blinded pilot study use eltrombopag combination ribavirin , pegylated-interferon , boceprevir , patient would otherwise treatment candidate low platelet count ( less 75x10^9/L ) . Administration drug ribavirin boceprevir standard care , one exception interferon . The total drug treatment period study patient range 32 - 56 week , depend liver disease stage viral response . Follow-up take place 12 24 week post treatment evaluate sustain viral response . Total study participation may require 1.5 year .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>Male female patient least 18 year age . Require platelet count 75 x 10^9 /L time screen . The patient must meet eligibility criterion drug involve . Only genotype 1 ( , b , indeterminate , mixed ) . Confirmed history chronic hepatitis C. Cirrhotic patient include . Liver image within 1 year exclude hepatocellular carcinoma ( HCC ) require patient cirrhosis . Patients without evidence cirrhosis meeting platelet criterion also admit study . Subjects must able provide inform consent , comply drug administration instruction , able complete study visit . Ability cover cost ribavirin , interferon , boceprevir also require . Female subject eligible : Nonpregnant , nonchildbearing potential , childbearing potential willing perform complete abstinence correctly use form birth control intercourse [ barrier method , intrauterine device , hormonal therapy , surgical sterilization female male partner ] . They must also willing pregnancy test perform every 4 week 6 month completion ribavirin . Male study participant must agree use condom female partner must partake one contraceptive method discuss 6 month completion ribavirin therapy . A history chronic infection ( i.e. , HIV HBV ) previous organ transplantation . A history platelet disorder . A poorly control underlying medical illness ( i.e. , diabetes , hypertension , coronary artery disease , congestive heart failure , etc. ) . Any contraindication study drug mention respective prescribing information . Patients decompensated cirrhosis define current evidence ascites , encephalopathy , infection variceal bleeding . All patient consider ChildPugh Class A . Patients AST/ALT level â‰¥ 500 IU/L exclude presumption another active liver disease . Patients must pregnant nursing . The study physician maintains right exclude patient medical condition list base laboratory value indicate chronic disease discover screening . Patients eye disease may exclude study ophthalmologist recommend treatment . Subjects know hypersensitivity reaction ( StevensJohnson syndrome , toxic , epidermal necrolysis , erythema multiforme ribavirin ) study drug component product . Subjects autoimmune hepatitis , hemoglobinopathy ( e.g. , thalassemia major , sicklecell anemia ) , creatinine clearance le 50 mL/min . Coadministration drug highly dependent CYP3A4/5 clearance CYP3A4/5 inducer ( See Table 2 boceprevir prescribe information ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Thrombocytopenia</keyword>
	<keyword>HCV</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Platelets</keyword>
	<keyword>Eltrombopag</keyword>
	<keyword>Liver Disease</keyword>
	<keyword>Antiviral Treatment</keyword>
</DOC>